Comedications and potential drug-drug interactions with direct-acting antivirals in hepatitis C patients on hemodialysis
Po-Yao Hsu, Yu-Ju Wei, Jia-Jung Lee, Sheng-Wen Niu, Jiun-Chi Huang, Cheng-Ting Hsu, Tyng-Yuan Jang, Ming-Lun Yeh, Ching-I Huang, Po-Cheng Liang, Yi-Hung Lin, Ming-Yen Hsieh, Meng-Hsuan Hsieh, Szu-Chia Chen, Chia-Yen Dai, Zu-Yau Lin, Shinn-Cherng Chen, Jee-Fu Huang, Jer-Ming Chang, Shang-Jyh Hwang, Wan-Long Chuang, Chung-Feng Huang, Yi-Wen Chiu, Ming-Lung Yu
Clin Mol Hepatol. 2021;27(1):186-196.   Published online 2020 Dec 3     DOI: https://doi.org/10.3350/cmh.2020.0180
Citations to this article as recorded by Crossref logo
Drug–Drug Interactions With Over-The-Counter Medicines: Mind the Unprescribed
Oliver Scherf-Clavel
Therapeutic Drug Monitoring.2022; 44(2): 253.     CrossRef
Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5
Chen-Hua Liu, Jia-Horng Kao
Hepatology International.2022; 16(5): 1001.     CrossRef
Drug-drug interactions between antithrombotics and direct-acting antivirals in hepatitis C virus (HCV) patients: A brief, updated report
Mario Enrico Canonico, Giuseppe Damiano Sanna, Roberta Siciliano, Fernando Scudiero, Giovanni Esposito, Guido Parodi
Frontiers in Pharmacology.2022;[Epub]     CrossRef
Evaluation of US Food and Drug Administration Drug Label Recommendations for Coadministration of Antivirals and Acid‐Reducing Agents
Tyler Shugg, Nicholas R. Powell, Patrick J. Marroum, Todd C. Skaar, Islam R. Younis
Clinical Pharmacology & Therapeutics.2022; 112(5): 1088.     CrossRef
Drug–drug interactions between direct-acting antivirals and co-medications: a territory-wide cohort study
Vicki Wing-Ki Hui, Christopher Langjun Au, Amy Shuk Man Lam, Terry Cheuk-Fung Yip, Yee-Kit Tse, Jimmy Che-To Lai, Henry Lik-Yuen Chan, Vincent Wai-Sun Wong, Grace Lai-Hung Wong
Hepatology International.2022; 16(6): 1318.     CrossRef
HCV GT1b-patient with alanine aminotransferase elevation and sustained virologic response achieved by grazoprevir/elbasvir discontinuation
Hiroshi Takahashi, Tatsuo Kanda, Naoki Matsumoto, Taku Mizutani, Tomohiro Kaneko, Masayuki Honda, Yoichiro Yamana, Tomotaka Ishii, Mariko Kumagawa, Reina Sasaki, Ryota Masuzaki, Kazushige Nirei, Hiroaki Yamagami, Masahiro Ogawa, Shunichi Matsuoka, Mitsuhi
Future Virology.2021; 16(3): 161.     CrossRef
Real-world experience of serial serum levels of GS-331007 in chronic hepatitis C hemodialysis patients during and after sofosbuvir/velpatasvir therapy
Chung-Feng Huang, Yu-Ju Wei, Yu-Tse Wu, Yi-Wen Chiu, Ming-Lung Yu
Journal of Hepatology.2021; 75(4): 1006.     CrossRef